SCHEMBL6763004

SCHEMBL6763004

O=C(NC1CCC(O)CC1)c1ccccc1Oc1nn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SLC6A12 P48065 1/20 0.46
BRD4 O60885 1/20 0.46
ALDH1A1 P00352 1/20 0.45
DRD4 P21917 1/20 0.45
SGMS2 Q8NHU3 1/20 0.44
CNR1 P21554 5/20 0.44
CNR2 P34972 5/20 0.44
SMYD3 Q9H7B4 1/20 0.44
ACHE P22303 1/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GUCY1B2 O75343 1/20 0.44
CYP1A2 P05177 1/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763571 0.81 CNR1 (0.41) MEN1KMT2ACNR1CNR2ACHE
SCHEMBL6763568 0.81 CNR1 (0.41) MEN1KMT2ACNR1CNR2ACHE
SCHEMBL6760256 0.81 CNR1 (0.41) MEN1KMT2ACNR1CNR2ACHE
SCHEMBL6760254 0.81 CNR1 (0.41) MEN1KMT2ACNR1CNR2ACHE
SCHEMBL6762478 0.81 USP30 (0.44) DRD4CNR1CNR2ACHEPOLB
SCHEMBL6763555 0.80 CNR1 (0.56) ALDH1A1CNR1CNR2ACHEPOLB
SCHEMBL6764315 0.79 KDM4E (0.58) MEN1KMT2AALDH1A1CNR1CNR2
SCHEMBL6762228 0.79 ACKR3 (0.47) ACHEKDM4EGUCY1B2CYP1A2CHRM2
SCHEMBL6766831 0.77 CYP1A2 (0.61) MEN1KMT2AALDH1A1CNR1CNR2
SCHEMBL6764331 0.76 KDM4E (0.46) CNR1CNR2ACHEPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US claimed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO claimed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 MEN1 2433/4885KMT2A 4490/4885SLC6A12 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.